m (Protected "Moxifloxacin (ophthalmic)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
(One intermediate revision by one other user not shown)
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Moxifloxacin (ophthalmic) in adult patients.
<!--Overview-->
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Moxifloxacin (ophthalmic) in adult patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Moxifloxacin (ophthalmic) in pediatric patients.
|genericName=
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Moxifloxacin (ophthalmic) in pediatric patients.
|alcohol=Alcohol-Moxifloxacin (ophthalmic) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
*VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
:*Corynebacterium species
:*Micrococcus luteus
:*Staphylococcus aureus
:*Staphylococcus epidermidis
:*Staphylococcus haemolyticus
:*Staphylococcus hominis
:*Staphylococcus warneri
:*Streptococcus pneumoniae
:*Streptococcus viridans group
:*Acinetobacter lwoffii
:*Haemophilus influenzae
:*Haemophilus parainfluenzae
:*Chlamydia trachomatis
*Dosing Information
:*Instill one drop in the affected eye 3 times a day for 7 days.
:*4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base.
<!--Off-Label Use and Dosage (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport=
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Pediatric Indications and Dosage-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=
=====Bacterial Conjunctivitis=====
*Dosing Information
:*Instill one drop in the affected eye 3 times a day for 7 days.
:*4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base.
<!--Off-Label Use and Dosage (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Contraindications-->
|contraindications=
*VIGAMOX® solution is contraindicated in patients with a history of [[hypersensitivity]] to moxifloxacin, to other quinolones, or to any of the components in this medication.
<!--Warnings-->
|warnings=
====Precautions====
*NOT FOR INJECTION. VIGAMOX® solution is for topical ophthalmic use only and should not be injected [[subconjunctivally]] or introduced directly into the anterior chamber of the eye.
*In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal [[hypersensitivity]] (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by [[cardiovascular]] collapse, [[loss of consciousness]], [[angioedema]] (including laryngeal, pharyngeal or facial edema), airway obstruction, [[dyspnea]], [[urticaria]], and [[itching]]. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute [[hypersensitivity]] reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.
*As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
*Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial [[conjunctivitis]].
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=
*Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.
*The most frequently reported ocular adverse events were [[conjunctivitis]], decreased visual acuity, dry eye, [[keratitis]], ocular discomfort, ocular [[hyperemia]], ocular pain, ocular [[pruritus]], [[subconjunctival hemorrhage]], and [[tearing]]. These events occurred in approximately 1-6% of patients.
*Nonocular adverse events reported at a rate of 1-4% were [[fever]], increased [[cough]], [[infection]], [[otitis media]], [[pharyngitis]], [[rash]], and [[rhinitis]].
<!--Postmarketing Experience-->
|postmarketing=
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
<!--Drug Interactions-->
|drugInteractions=
*Drug-drug interaction studies have not been conducted with VIGAMOX® solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these [[cytochrome P450]] isozymes.
<!--Use in Specific Populations-->
|useInPregnancyFDA=
* '''Pregnancy Category C'''
*Teratogenic Effects
:*Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of teratogenicity when pregnant Cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.
:*Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX® solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=
*Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when VIGAMOX® solution is administered to a nursing mother.
|useInPed=
*The safety and effectiveness of VIGAMOX® solution in infants below 1 year of age have not been established.
|useInGeri=
*No overall differences in safety and effectiveness have been observed between elderly and younger patients.
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
<!--Administration and Monitoring-->
|administration=
* Topical
|monitoring=
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
<!--IV Compatibility-->
|IVCompat=
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
<!--Overdosage-->
|overdose=
===Chronic Overdose===
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
* The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
*The mechanism of action for [[quinolones]], including moxifloxacin, is different from that of [[macrolides]], [[aminoglycosides]], or [[tetracyclines]]. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin. There is no cross-resistance between moxifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic moxifloxacin and some other quinolones.
<!--Structure-->
|structure=
* VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position.
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
*1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4-b]pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid, monohydrochloride. Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder. Each mL of VIGAMOX® solution contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base.
*Contains: Active: Moxifloxacin 0.5% (5 mg/mL); Inactives: Boric acid, sodium chloride, and purified water. May also contain hydrochloric acid/sodium hydroxide to adjust pH to approximately 6.8.
*VIGAMOX® solution is an isotonic solution with an osmolality of approximately 290 mOsm/kg.
<!--Pharmacodynamics-->
|PD=
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
<!--Pharmacokinetics-->
|PK=
*Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX® solution 3 times a day. The mean steady-state Cmax (2.7 ng/mL) and estimated daily exposure AUC (45 ng•hr/mL) values were 1,600 and 1,000 times lower than the mean Cmax and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.
=====Microbiology=====
*In vitro resistance to moxifloxacin develops via multiple-step mutations. Resistance to moxifloxacin occurs in vitro at a general frequency of between 1.8 x 10-9 to < 1 x 10-11 for Gram-positive bacteria.
*Moxifloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:
*Aerobic Gram-positive microorganisms:
:*[[Corynebacterium]] species*
:*Micrococcus luteus*
:*[[Staphylococcus aureus]]
:*[[Staphylococcus epidermidis]]
:*[[Staphylococcus haemolyticus]]
:*[[Staphylococcus hominis]]
:*Staphylococcus warneri*
:*[[Streptococcus pneumoniae]]
:*[[Streptococcus viridans]] group
*Aerobic Gram-negative microorganisms:
:*Acinetobacter lwoffii*
:*[[Haemophilus influenzae]]
:*[[Haemophilus parainfluenzae]]*
*Other microorganisms:
:*[[Chlamydia trachomatis]]
.*Efficacy for this organism was studied in fewer than 10 infections.
*The following in vitro data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of VIGAMOX® solution in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials.
*The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the in vitro systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Moxifloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2 μg/ml or less (systemic susceptible breakpoint) against most (≥ 90%) strains of the following ocular pathogens.
*Aerobic Gram-positive microorganisms:
:*[[Listeria monocytogenes]]
:*[[Staphylococcus saprophyticus]]
:*[[Streptococcus agalactiae]]
:*Streptococcus mitis
:*[[Streptococcus pyogenes]]
:*Streptococcus Group C, G and F
*Aerobic Gram-negative microorganisms:
:*Acinetobacter baumannii
:*Acinetobacter calcoaceticus
:*Citrobacter freundii
:*Citrobacter koseri
:*Enterobacter aerogenes
:*Enterobacter cloacae
:*[[Escherichia coli]]
:*Klebsiella oxytoca
:*[[Klebsiella pneumoniae]]
:*[[Moraxella catarrhalis]]
:*[[Morganella morganii]]
:*[[Neisseria gonorrhoeae]]
:*[[Proteus mirabilis]]
:*[[Proteus vulgaris]]
:*Pseudomonas stutzeri
*Anaerobic microorganisms:
:*[[Clostridium perfringens]]
:*Fusobacterium species
:*Prevotella species
:*[[Propionibacterium acnes]]
*Other microorganisms:
:*[[Chlamydia pneumoniae]]
:*[[Legionella pneumophila]]
:*[[Mycobacterium avium]]
:*[[Mycobacterium marinum]]
:*[[Mycoplasma pneumoniae]]
<!--Nonclinical Toxicology-->
|nonClinToxic=
*Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose for a 50 kg person, on a mg/kg basis).
*Moxifloxacin was not mutagenic in four bacterial strains used in the Ames Salmonella reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity in vivo in a micronucleus test or a dominant lethal test in mice.
*Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 21,700 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.
<!--Clinical Studies-->
|clinicalStudies=
*In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, VIGAMOX® solution produced clinical cures on day 5-6 in 66% to 69% of patients treated for bacterial [[conjunctivitis]]. Microbiological success rates for the eradication of baseline pathogens ranged from 84% to 94%. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.
<!--How Supplied-->
|howSupplied=
* VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
*3 mL in a 4 mL bottle - NDC 0065-4013-03
*Storage: Store at 2°C- 25°C (36°F - 77°F).
<!--Patient Counseling Information-->
|fdaPatientInfo=
*Patients should be advised not to touch the dropper tip to any surface to avoid contaminating the contents.
*Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial [[conjunctivitis]].
*Systemically administered quinolones including moxifloxacin have been associated with [[hypersensitivity]] reactions, even following a single dose. Patients should be told to discontinue use immediately and contact their physician at the first sign of a [[rash]] or [[allergic]] reaction.
<!--Precautions with Alcohol-->
|alcohol=
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
<!--Brand Names-->
|brandNames=
* VIGAMOX®<ref>{{Cite web | title = VIGAMOX - moxifloxacin hydrochloride solution | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=750fd60e-c0c4-4f32-8301-6baa3516aef2 }}</ref>
<!--Look-Alike Drug Names-->
|lookAlike=
<!--Drug Shortage Status-->
|drugShortage=
}}
<!--Pill Image-->
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}
<!--Label Display Image-->
{{LabelImage
|fileName={{PAGENAME}}02.png|This image is provided by the National Library of Medicine.
}}
{{LabelImage
|fileName={{PAGENAME}}03.png|This image is provided by the National Library of Medicine.
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Corynebacterium species
Micrococcus luteus
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus hominis
Staphylococcus warneri
Streptococcus pneumoniae
Streptococcus viridans group
Acinetobacter lwoffii
Haemophilus influenzae
Haemophilus parainfluenzae
Chlamydia trachomatis
Dosing Information
Instill one drop in the affected eye 3 times a day for 7 days.
4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Moxifloxacin (ophthalmic) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Moxifloxacin (ophthalmic) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Bacterial Conjunctivitis
Dosing Information
Instill one drop in the affected eye 3 times a day for 7 days.
4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Moxifloxacin (ophthalmic) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Moxifloxacin (ophthalmic) in pediatric patients.
Contraindications
VIGAMOX® solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.
Warnings
Precautions
NOT FOR INJECTION. VIGAMOX® solution is for topical ophthalmic use only and should not be injected subconjunctivally or introduced directly into the anterior chamber of the eye.
In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.
As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.
There is limited information regarding Postmarketing Experience of Moxifloxacin (ophthalmic) in the drug label.
Drug Interactions
Drug-drug interaction studies have not been conducted with VIGAMOX® solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of teratogenicity when pregnant Cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.
Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX® solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Moxifloxacin (ophthalmic) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Moxifloxacin (ophthalmic) during labor and delivery.
Nursing Mothers
Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when VIGAMOX® solution is administered to a nursing mother.
Pediatric Use
The safety and effectiveness of VIGAMOX® solution in infants below 1 year of age have not been established.
Geriatic Use
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Gender
There is no FDA guidance on the use of Moxifloxacin (ophthalmic) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Moxifloxacin (ophthalmic) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Moxifloxacin (ophthalmic) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Moxifloxacin (ophthalmic) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Moxifloxacin (ophthalmic) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Moxifloxacin (ophthalmic) in patients who are immunocompromised.
Administration and Monitoring
Administration
Topical
Monitoring
There is limited information regarding Monitoring of Moxifloxacin (ophthalmic) in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Moxifloxacin (ophthalmic) in the drug label.
Overdosage
Chronic Overdose
There is limited information regarding Chronic Overdose of Moxifloxacin (ophthalmic) in the drug label.
The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin. There is no cross-resistance between moxifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic moxifloxacin and some other quinolones.
Structure
VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position.
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4-b]pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid, monohydrochloride. Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder. Each mL of VIGAMOX® solution contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base.
Contains: Active: Moxifloxacin 0.5% (5 mg/mL); Inactives: Boric acid, sodium chloride, and purified water. May also contain hydrochloric acid/sodium hydroxide to adjust pH to approximately 6.8.
VIGAMOX® solution is an isotonic solution with an osmolality of approximately 290 mOsm/kg.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Moxifloxacin (ophthalmic) in the drug label.
Pharmacokinetics
Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX® solution 3 times a day. The mean steady-state Cmax (2.7 ng/mL) and estimated daily exposure AUC (45 ng•hr/mL) values were 1,600 and 1,000 times lower than the mean Cmax and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.
Microbiology
In vitro resistance to moxifloxacin develops via multiple-step mutations. Resistance to moxifloxacin occurs in vitro at a general frequency of between 1.8 x 10-9 to < 1 x 10-11 for Gram-positive bacteria.
Moxifloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:
.*Efficacy for this organism was studied in fewer than 10 infections.
The following in vitro data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of VIGAMOX® solution in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials.
The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the in vitro systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Moxifloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2 μg/ml or less (systemic susceptible breakpoint) against most (≥ 90%) strains of the following ocular pathogens.
Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose for a 50 kg person, on a mg/kg basis).
Moxifloxacin was not mutagenic in four bacterial strains used in the Ames Salmonella reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when v79 cells were used. Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity in vivo in a micronucleus test or a dominant lethal test in mice.
Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 21,700 times the highest recommended total daily human ophthalmic dose. At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.
Clinical Studies
In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, VIGAMOX® solution produced clinical cures on day 5-6 in 66% to 69% of patients treated for bacterial conjunctivitis. Microbiological success rates for the eradication of baseline pathogens ranged from 84% to 94%. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.
How Supplied
VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
3 mL in a 4 mL bottle - NDC 0065-4013-03
Storage: Store at 2°C- 25°C (36°F - 77°F).
Storage
There is limited information regarding Moxifloxacin (ophthalmic) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Moxifloxacin (ophthalmic)
|?Pill Name
|?Drug Name
|?Pill Ingred
|?Pill Imprint
|?Pill Dosage
|?Pill Color
|?Pill Shape
|?Pill Size (mm)
|?Pill Scoring
|?NDC
|?Drug Author
|format=template
|template=DrugPageImages
|mainlabel=-
|sort=Pill Name
}}
Patients should be advised not to touch the dropper tip to any surface to avoid contaminating the contents.
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Patients should be told to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.
Precautions with Alcohol
Alcohol-Moxifloxacin (ophthalmic) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
01.png){kind=link}